Nordic Nanovector, a biotechnology company, agreed to acquire Thor Medical, a manufacturer of radionuclides. Financial terms were not disclosed. "Given the complementary focus and expertise in our two companies, the Nordic Nanovector Board and I believe the proposed acquisition of Thor Medical represents a compelling option for Nordic Nanovector and its shareholders. There is increasing interest in the development of radionuclide-based anti-cancer therapies, and the combined company will have a significant opportunity to address this growing market," Ludvik Sandnes, Nordic Nanovector Interim CEO & CFO.